(Q53161291)

12 May 2018

title

Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL) (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

21 November 2024

0 references

1 reference

diffuse large B-cell lymphoma

1 reference

Olivera Markovic

1

1 reference

12 May 2018

Dragomir Marisavljevic

2

1 reference

12 May 2018

Vesna Cemerikic

3

1 reference

12 May 2018

Maja Perunicic

4

1 reference

12 May 2018

Sasa Savic

5

1 reference

12 May 2018

Branka Filipovic

6

1 reference

12 May 2018

Biljana Mihaljevic

7

1 reference

12 May 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21198858

21 November 2024

publication date

1 March 2011

1 reference

12 May 2018

March 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21198858

full work available at URL

21 November 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0609.2010.01567.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2010.01567.x/fullpdf

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

European Journal of Haematology

21 November 2024

published in

1 reference

12 May 2018

volume

86

1 reference

12 May 2018

issue

3

1 reference

12 May 2018

page(s)

246-255

1 reference

12 May 2018

State-of-the-art therapeutics: diffuse large B-cell lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Prognostic biomarkers in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

The biochemistry of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Mitochondrial control of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Dysregulation of apoptosis genes in hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Building an outcome predictor model for diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Impairment of death-inducing signalling complex formation in CD95-resistant human primary lymphoma B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Survivin splice variants regulate the balance between proliferation and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

The role of c-FLIP in modulation of CD95-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Death and anti-death: tumour resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

FAS Death Domain Deletions and Cellular FADD-like Interleukin 1 Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2010.01567.X

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

21 January 2018

15

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 November 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma

21 November 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma

21 November 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes

21 November 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas

21 November 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation

21 November 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis

21 November 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2010.01567.X

21 November 2024

Identifiers

1 reference

12 May 2018

1 reference

12 May 2018